3,4-二氨基苯甲脒 | 68827-43-0

• 物质功能分类: 化学试剂 - 有机试剂 - 亚氨、脒
• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 3,4-二氨基苯甲脒
• 中文别名: 二烷基二硫代磷酸锌
• 英文名称: 3,4-diaminobenzamidine
• 英文别名: 4-amidino-1,2-phenylenediamine；3,4-Diaminobenzimidamide；3,4-diaminobenzenecarboximidamide
• CAS: 68827-43-0
• 化学式: C₇H₁₀N₄
• 分子量: 150.183
• InChiKey: YQQCEOMFCLGSTF-UHFFFAOYSA-N

物化性质

• 沸点：
  363.4±52.0 °C(Predicted)
• 密度：
  1.44

计算性质

• 辛醇/水分配系数(LogP)：
  -0.4
• 重原子数：
  11
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  102
• 氢给体数：
  4
• 氢受体数：
  3

安全信息

• 海关编码：
  2925290090
• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H335

反应信息

• 作为反应物：
  描述：

  3,4-二氨基苯甲脒 在 palladium on activated charcoal 盐酸 、 氢气 、 对苯醌 作用下， 以 乙醇 、 水 为溶剂， 25.0 ℃ 、344.73 kPa 条件下， 反应 6.5h， 生成 2-(3,4-diaminophenyl)-1H-benzimidazole-5-carboxamidine
  参考文献：
  名称：

  Synthesis and DNA Interactions of Benzimidazole Dications Which Have Activity against Opportunistic Infections

  摘要：

  Considerable evidence now indicates that DNA is the receptor site for dicationic benzimidazole anti-opportunistic infections agents (Bell, C. A.; Dykstra, C. C.; Naiman, N. A. I.; Cory, M:.; Fairley, T. A.; Tidwell, R. R. Antimicrob. Agents Chemother. 1993, 37, 2668-2673. Tidwell, R. R.; Jones, S. K; Naiman, N. A.; Berger, I. C.; Brake, W. R.; Dykstra, C, C.; Hall, J. E. Antimicrob. Agents Chemother. 1993, 37, 1713-1716). To obtain additional information on benzimidazole-receptor complexes, the syntheses and DNA interactions of series of symmetric benzimidazole cations, linked by alkyl or alkenyl groups, have been evaluated. Biophysical techniques, thermal denaturation measurement (Delta T-m), kinetics, and circular dichroism (CD) have been used in conjunction with NMR and molecular modeling to evaluate the affinities, binding mode, and structure of complexes formed between these compounds and DNA. All of the compounds bind strongly to DNA samples with four or more consecutive AT base pairs, and they bind negligibly to GC rich DNA or to RNA. Spectral and kinetics characteristics of the benzimidazole complexes indicate that the compounds bind in the DNA minor groove at AT sequences. NMR and molecular modeling of the complex formed between an ethylene-linked benzimidazole derivative, 5, and the self-complementary oligomer d(GCGAATTCGC) have been used to establish structural details for the minor groove complex. These results have been used as a starting point for molecular mechanics calculations to refine the model of the minor groove-benzimidazole complex and to draw conclusions regarding the molecular basis for the effects of substituent changes on benzimidazole-DNA affinities.

  DOI：

  10.1021/jm9507946
• 作为产物：
  描述：

  Methyl 4-amino-3-nitrobenzenecarboximidate 在 palladium on activated charcoal 氨 、 氢气 作用下， 以 甲醇 、 乙醇 为溶剂， 反应 6.0h， 生成 3,4-二氨基苯甲脒
  参考文献：
  名称：

  烷基和芳基连接的双（ami基苯并咪唑）和双（ami基吲哚）的结构，DNA小沟结合和碱基对特异性。

  摘要：

  已经制备了一系列具有变化的连接链的双（ami基苯并咪唑）和双（ami基吲哚），所述连接链连接芳族基团并且对碱性a基进行了各种修饰。小牛胸腺（CT）DNA和核酸均聚物[poly（dA）.poly（dT），poly（dA-dT）.poly-（dA-dT）和poly（dG-dC）.poly（dG-dC） ）]已经通过热变性（ΔTm）和粘度研究了这些化合物的结合性能。该化合物对poly（dA）.poly（dT）和poly（dA-dT）.poly（dA-dT）的亲和力大于对poly（dG-dC）.poly（dG-dC）的亲和力。粘度滴定表明该化合物不通过嵌入结合。分子模型研究和生物物理数据表明，分子与CT DNA和均聚物的小沟结合。分子形状的分析与这种核酸结合模式一致。与苯并咪唑环相连的亚甲基数量为偶数的化合物比亚甲基数量为奇数的化合物对DNA的亲和力更高。确定分子中四个定义的基团的曲率半径的分子模

  DOI：

  10.1021/jm00064a008

文献信息

• [EN] 2-'5-(5-CARBAMIMIDOYL-1H-HETEROARYL)-6-HYDROXYBIPHENYL-3-YL!- CARBOXYLIC ACID DERIVATIVES AS FACTOR VIIA INHIBITORS<br/>[FR] DERIVES D'ACIDE 2[-5-(5-CARBAMIMIDOYL-1H-HETEROARYL)-6-HYDROXYBIPHENYL-3-YL] CARBOXYLIQUE COMME INHIBITEURS DU FACTEUR VIIA
  申请人：AXYS PHARM INC

  公开号：WO2004062661A1

  公开（公告）日：2004-07-29

  The present invention relates to novel inhibitors of Factors VIIa, IXa, Xa, XIa, in particular Factor VIIa, pharmaceutical compositions comprising these inhibitors, and methods for using these inhibitors for treating or preventing thromboembolic disorders. Processes for preparing these inhibitors are also disclosed.

  本发明涉及新型因子VIIa、IXa、Xa、XIa的抑制剂，特别是因子VIIa，包括这些抑制剂的药物组合物，以及使用这些抑制剂治疗或预防血栓栓塞性疾病的方法。还公开了制备这些抑制剂的方法。
• 2- [5- (5-carbamimidoyl-1H-heteroaryl)-6-hydroxybiphenyl-3-yl]-succinic acid derivatives as factor viia inhibitors
  申请人：Axys Pharmaceuticals, Inc.

  公开号：US20030114457A1

  公开（公告）日：2003-06-19

  The present invention relates to novel inhibitors of Factors VIIa, IXa, Xa, XIa, in particular Factor VIIa, pharmaceutical compositions comprising these inhibitors, and methods for using these inhibitors for treating or preventing thromboembolic disorders. Processes for preparing these inhibitors are also disclosed.

  本发明涉及新型因子VIIa、IXa、Xa、XIa的抑制剂，特别是因子VIIa，包括这些抑制剂的药物组合物，以及利用这些抑制剂治疗或预防血栓栓塞性疾病的方法。还公开了制备这些抑制剂的方法。
• Sulfonamide bridging compounds that inhibit tryptase activity
  申请人：Array Biopharma Inc.

  公开号：US06221914B1

  公开（公告）日：2001-04-24

  The present invention is directed to compounds which are capable of inhibiting the activity of tryptase. Such compounds are useful in the treatment or prevention of inflammatory disease, particularly those disease states which are mediated by mast cell activation. Also encompassed by the invention are formulations comprising the noted compounds, processes for preparing such compounds and methods for treating or preventing an inflammatory disease.

  本发明涉及一种能够抑制色氨酸蛋白酶活性的化合物。这些化合物对于治疗或预防炎症性疾病是有用的，特别是那些由肥大细胞激活介导的疾病状态。该发明还包括含有上述化合物的配方、制备这种化合物的方法以及治疗或预防炎症性疾病的方法。
• New quinoline-arylamidine hybrids: Synthesis, DNA/RNA binding and antitumor activity
  作者：Luka Krstulović、Ivana Stolić、Marijana Jukić、Teuta Opačak-Bernardi、Kristina Starčević、Miroslav Bajić、Ljubica Glavaš-Obrovac

  DOI：10.1016/j.ejmech.2017.05.054

  日期：2017.9

  (groups I (2a-g) and II (5a-g)) or flexible -NH-CH2-CH2-O- (groups III (8a-g) and IV (10a-g)) linker were synthesized, and their DNA/RNA binding properties and cytotoxic activity were tested, against several human cancer lines. The compounds and their interaction with DNA and RNA were studied by UV–Vis and CD spectroscopy. The obtained results showed that the binding affinity of the investigated compounds

  通过刚性-O-（I组（2a-g）和II（5a-g））或柔性-NH-CH 2 -CH 2 - O-（第三组（8a-g）和第四组（10a-g））合成了连接子，并测试了其对几种人类癌症细胞系的DNA / RNA结合特性和细胞毒性活性。通过UV-Vis和CD光谱研究了这些化合物及其与DNA和RNA的相互作用。获得的结果表明，所研究化合物的结合亲和力随着能够与ds-多核苷酸形成氢键的基团的长度和数目的增加而成比例地增加。通过降低所研究化合物的结构刚度还可以实现结合的改善，新的杂合化合物优先结合ctDNA。对于大部分的DNA / RNA槽是占主导地位的结合位点，除了从基团的化合物II其在polyA-polyU中的插入是主要的结合模式。通过MTT测试对正常（MDCK1），癌（HeLa和CaCo2）和白血病细胞系（Raji和K462）的抗增殖作用进行了测试。所有研究的化合物的GI 50值范围从5到大于100×10
• Synthesis and in vitro activity of dicationic bis-benzimidazoles as a new class of anti-MRSA and anti-VRE agents
  作者：Laixing Hu、Maureen L. Kully、David W. Boykin、Norman Abood

  DOI：10.1016/j.bmcl.2009.01.075

  日期：2009.3

  class of novel bis-benzimidazole diamidine compounds have been synthesized and evaluated for in vitro antibacterial activities, including drug-resistant bacterial strains. Anti-MRSA and anti-VRE activities of the most potent compound 1 were more active than Vancomycin. The mechanism of action for this class of compounds appears to be different from existing antibiotics. Bis-benzimidazole diamidine compounds

  已经合成了一类新型的新型双苯并咪唑二am化合物，并对其体外抗菌活性进行了评估，包括耐药菌菌株。最有效的化合物1的抗MRSA和抗VRE活性比万古霉素更具活性。这类化合物的作用机理似乎不同于现有的抗生素。双-苯并咪唑二am化合物作为一类新的有效的抗MRSA和抗VRE剂具有潜力，需要进一步研究。